截至2025年一季报，共有21家机构持仓通策医疗，其中基金18家、其他3家，合计持股数20958.98万 股，持股市值94.88亿元。 通策医疗股份有限公司的主营业务是口腔医疗服务的提供、研发。公司的主要产品是医疗服务、产品销 售、建筑工程、综合服务费。 6月24日，通策医疗今日收盘40.74元，上涨1.34%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到35.58倍，总市值182.23亿元。 从行业市盈率排名来看，公司所处的医疗服务行业市盈率平均39.95倍，行业中值41.77倍，通策医疗排 名第26位。 序号股票简称PE(TTM)PE(静)市净率总市值(元)10通策医疗35.5836.344.33182.23亿行业平均 39.9545.993.45157.13亿行业中值41.7751.452.6755.94亿1药明康德17.1720.313.081919.79亿2康龙化成 22.5823.533.00421.97亿3诺泰生物24.6829.954.41121.11亿4普蕊斯25.9022.182.0023.60亿5诺禾致源 27.5128.432.2155.94亿6诺思格30.8131.4 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Tongce Medical, which operates in the dental healthcare sector [1][2] - As of May 16, Tongce Medical's closing price was 40.62 yuan, with a decline of 1.43%, resulting in a rolling PE ratio of 35.47 times and a total market capitalization of 18.169 billion yuan [1] - The average PE ratio for the healthcare services industry is 37.33 times, with a median of 39.22 times, positioning Tongce Medical at 26th place within the industry [1][2] Group 2 - As of the first quarter of 2025, 21 institutions held shares in Tongce Medical, including 18 funds, with a total holding of 209.5898 million shares valued at 9.488 billion yuan [1] - The main business of Tongce Medical includes providing dental healthcare services and research, with key products being medical services, product sales, construction engineering, and comprehensive service fees [1] - The latest financial results for the first quarter of 2025 show that the company achieved an operating income of 745 million yuan, a year-on-year increase of 5.11%, and a net profit of 184 million yuan, reflecting a year-on-year growth of 6.22%, with a gross profit margin of 44.21% [1]